Carriers of Rare Missense Variants in IFIH1 Are Protected from Psoriasis

Testing of ∼25,000 putative functional single-nucleotide polymorphisms (SNPs) across the human genome in a genetic association study has identified three psoriasis genes, IL12B, IL23R, and IL13. We now report evidence for the association of psoriasis risk with missense SNPs in the interferon induced...

Full description

Saved in:
Bibliographic Details
Published in:Journal of investigative dermatology Vol. 130; no. 12; pp. 2768 - 2772
Main Authors: Li, Yonghong, Liao, Wilson, Cargill, Michele, Chang, Monica, Matsunami, Nori, Feng, Bing-Jian, Poon, Annie, Callis-Duffin, Kristina P., Catanese, Joseph J., Bowcock, Anne M., Leppert, Mark F., Kwok, Pui-Yan, Krueger, Gerald G., Begovich, Ann B.
Format: Journal Article
Language:English
Published: New York, NY Elsevier Inc 01-12-2010
Nature Publishing Group
Elsevier Limited
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Testing of ∼25,000 putative functional single-nucleotide polymorphisms (SNPs) across the human genome in a genetic association study has identified three psoriasis genes, IL12B, IL23R, and IL13. We now report evidence for the association of psoriasis risk with missense SNPs in the interferon induced with helicase C domain 1 gene (IFIH1). The rare alleles of two independent SNPs were associated with decreased risk of psoriasis—rs35667974 (Ile923Val): odds ratio (OR) for minor allele carriers is 0.43, P=2.36 × 10−5 (2,098 cases vs. 1,748 controls); and rs10930046 (His460Arg): OR for minor allele carriers is 0.51, P=6.47 × 10−4 (2,098 cases vs. 1,744 controls). Compared to noncarriers, carriers of the 923Val and/or 460Arg variants were protected from psoriasis (OR=0.46, P=5.56 × 10−8). To our knowledge, these results suggest that IFIH1 is a previously unreported psoriasis gene.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
Current address: Roche Diagnostics, Pleasanton, California, USA
Current address: Navigenics, Foster City, California, USA
ISSN:0022-202X
1523-1747
DOI:10.1038/jid.2010.214